COVID-19: Clinical aspects and therapeutics responses
Open Access
- 1 August 2020
- journal article
- research article
- Published by Elsevier BV in Saudi Pharmaceutical Journal
- Vol. 28 (8), 1004-1008
- https://doi.org/10.1016/j.jsps.2020.06.022
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81870942, 81471174, 81520108011)
This publication has 19 references indexed in Scilit:
- Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)Pharmacological Research, 2020
- Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, ChinaJAMA, 2020
- INDUCTION OF PRO-INFLAMMATORY CYTOKINES (IL-1 and IL-6) AND LUNG INFLAMMATION BY CORONAVIRUS-19 (COVI-19 or SARS-CoV-2): ANTI-INFLAMMATORY STRATEGIES2020
- Novel coronavirus: how things are in WuhanClinical Microbiology & Infection, 2020
- Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studiesBioScience Trends, 2020
- Department of ErrorThe Lancet, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Effect of Lianhuaqingwen Capsules on Airway Inflammation in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary DiseaseEvidence-Based Complementary and Alternative Medicine, 2014
- Natural herbal medicine Lianhuaqingwen capsule anti-influenza A (H1N1) trial: a randomized, double blind, positive controlled clinical trial.2011